Tyra Biosciences, Inc. (TYRA) Stock Analysis
A live, multi-source view of Tyra Biosciences, Inc. (TYRA): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Sector: Healthcare · Industry: Biotechnology · United States · 87 employees · tyra.bio
Key statistics · as of 2026-09-06
As of 2026-09-06, Tyra Biosciences, Inc. (TYRA) had a market capitalization of $1.71B (forward -9.7) and a beta of 0.73; the shares traded in a 52-week range of $11.70 – $40.65 (104.9% over the year).
- Market cap
- $1.71B
- Enterprise value
- $1.36B
- Forward P/E
- -9.7
- Price / book
- 4.83
- EPS (trailing)
- $-2.39
- EPS (forward)
- $-2.96
- Payout ratio
- 0.0%
- 52-week range
- $11.70 – $40.65
- 52-week change
- 104.9%
- Beta
- 0.73
- Average volume
- 734,203
- Shares outstanding
- 59.7M
- Short % of float
- 29.93%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Tyra Biosciences, Inc. (TYRA) last closed at $23.54 (the last completed close before that scan).
Technicals at the scan: RSI 41 (neutral territory), price -8.1% versus its 20-day average, 20-day versus 50-day average spread -10.3%, MACD histogram -0.05.
Sentiment inputs: 44% of recent Finnhub-scored headlines read bullish; analyst consensus score 77/100.
Next scheduled company event: in 54 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for TYRA in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
TYRA has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Tyra Biosciences, Inc. (TYRA) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell TYRA.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.